RBC Capital Downgrades Outset Medical(OM.US) to Hold Rating, Cuts Target Price to $3
RBC Capital Remains a Hold on Outset Medical (OM)
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Outset Medical Price Target Cut to $3.00/Share From $6.00 by RBC Capital
TD Cowen Maintains Buy on Outset Medical, Lowers Price Target to $3
Outset Medical Analyst Ratings
RBC Capital Reaffirms Their Hold Rating on Outset Medical (OM)
RBC Downgrades Outset Medical to Sector Perform From Outperform, Cuts Price Target to $3 From $6
Outset Medical: Resilient Performance and Strategic Initiatives Justify Buy Rating
Outset Medical up 15% Following Upgrade From RBC Capital Markets
Outset Medical Analyst Ratings
RBC Upgrades Outset Medical to Outperform From Sector Perform, Raises Price Target to $6 From $5
Analysts' Top Healthcare Picks: Outset Medical (OM), Cytokinetics (CYTK)
Bank of America Securities Remains a Sell on Outset Medical (OM)
Morgan Stanley Lowers Price Target on Outset Medical to $4.50 From $5.50, Keeps Equalweight Rating
Oppenheimer Sticks to Their Hold Rating for Outset Medical (OM)
RBC Capital Sticks to Its Hold Rating for Outset Medical (OM)
Outset Medical (OM.US) was first covered by BTIG and given a buy rating, with a target price of $6.00.
Outset Medical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Exact Sciences (EXAS) and DarioHealth (DRIO)